# A Study to Evaluate the Efficacy and Safety of MG-K10 in Participants Who Have Atopic Dermatitis

> **NCT07479615** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai Mabgeek Biotech.Co.Ltd** · enrollment: 498 (estimated)

## Conditions studied

- Atopic Dermatitis
- Atopic Eczema

## Interventions

- **BIOLOGICAL:** MG-K10 Humanized Monoclonal Antibody Injection

## Key facts

- **NCT ID:** NCT07479615
- **Lead sponsor:** Shanghai Mabgeek Biotech.Co.Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2029-01
- **Final completion:** 2029-01
- **Target enrollment:** 498 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07479615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07479615, "A Study to Evaluate the Efficacy and Safety of MG-K10 in Participants Who Have Atopic Dermatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07479615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*